Alzheimer's Disease Epidemiology Forecast 2025-2034

Alzheimer’s disease contributes to 60% to 70% of dementia cases. It affects about 24 million individuals across the globe, with the incidence increasing with advancing age. It is estimated that 1 in 10 people aged over 65 years have Alzheimer’s disease. On the other hand, 1 in 3 people aged above 85 years have the condition.

Alzheimer’s Disease Epidemiology Forecast Report Coverage

The “Alzheimer’s Disease Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Alzheimer’s disease. It projects the future incidence and prevalence rates of Alzheimer’s disease across various populations. The study covers age, gender, and type as major determinants of the Alzheimer’s disease-affected population. The report highlights patterns in the prevalence of Alzheimer’s disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Alzheimer’s disease in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Alzheimer’s Disease Overview

Alzheimer’s disease (AD) refers to a progressive neurodegenerative disorder, characterized by the accumulation of amyloid plaques and tau tangles in the brain. The condition primarily affects memory, thinking, and behavior. Memory loss, confusion, and difficulty with language are the early symptoms observed in Alzheimer's patients. A family history of Alzheimer's, advancing age, hypertension, diabetes, smoking, obesity, and lack of physical activity, are known to increase the risk of the condition.

Alzheimer’s Disease: Treatment Overview

To manage cognitive symptoms (memory, thinking, and problem-solving), cholinesterase inhibitors, such as Donepezil (Aricept), Rivastigmine (Exelon), and Galantamine (Razadyne), are prescribed that help increase the levels of acetylcholine, a neurotransmitter involved in memory and learning. Memantine (Namenda) is often used in combination with cholinesterase inhibitors for the treatment of moderate to severe Alzheimer’s disease. Anti-tau therapies are increasingly being explored to target tau tangles in the brain.

Epidemiology

The Alzheimer’s disease epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Alzheimer’s disease by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Alzheimer’s disease and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• About 24 million people are affected by Alzheimer’s disease worldwide, with 1 in 10 adults older than 65 having the condition.
• At age 45, the lifetime risk of developing Alzheimer’s is 1 in 10 for men and 1 in 5 for women, as per the Alzheimer’s Association.
• According to the World Health Organisation (WHO), Alzheimer's disease is the most prevalent form of dementia, accounting for 60% to 70% of all cases.
• Approximately 1 in 9 people aged 65 and older in the United States are living with Alzheimer’s disease. Young-onset Alzheimer's impacts around 110 in every 100,000 adults aged 30 to 64.

Country-wise Alzheimer’s Disease Epidemiology

The Alzheimer’s disease epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Alzheimer’s disease varies between countries owing to differences in genetic factors, healthcare systems, environmental influences, lifestyle factors, and social determinants of health, among others. Further, variations in diagnosis and reporting practices can impact prevalence rates in different regions. In the United States, an estimated 6.9 million adults aged above 65 years are living with Alzheimer’s disease, as per the 2024 report from the Alzheimer’s Association.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Alzheimer’s disease based on several factors.
• Alzheimer’s Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of Alzheimer’s disease are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of Alzheimer’s disease epidemiology in the 8 major markets?
• What will be the total number of patients with Alzheimer’s disease across the 8 major markets during the forecast period?
• What was the country-wise prevalence of Alzheimer’s disease in the 8 major markets in the historical period?
• Which country will have the highest number of Alzheimer’s disease patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Alzheimer’s disease during the forecast period of 2025-2034?
• What are the currently available treatments for Alzheimer’s disease?
• What are the disease risks, signs, symptoms, and unmet needs of Alzheimer’s disease?

This product will be delivered within 3-5 business days.